Affiliations 

  • 1 Faculty of Pharmacy, Universiti Kebangsaan Malaysia, Kuala Lumpur, Malaysia
  • 2 Hawke's Bay District Health Board, Hastings, New Zealand
  • 3 Carney Centre for Pharmacogenomics and Department of Pathology and Biomedical Science, University of Otago, Christchurch, Christchurch, New Zealand
Front Pharmacol, 2019;10:931.
PMID: 31507424 DOI: 10.3389/fphar.2019.00931

Abstract

We report two cases of metoclopramide-induced acute dystonia in pregnant women and consider the role of genetic variation in the pathogenesis of the adverse effect. By whole-gene sequencing, we found that both women were CYP2D6 poor metabolizers. We theorize that CYP2D6 governs the risk of metoclopramide-related acute dystonia through its role in the synthesis of serotonin, which inhibits the dopamine tone. The effect of CYP2D6 poor metabolism is exaggerated by rises in the estrogen levels during pregnancy, as the hormone augments dopamine sensitivity. Together, the two factors may create a hyper-dopaminergic state that is easily upset by metoclopramide, resulting in acute dystonia.

* Title and MeSH Headings from MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.